about
Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boostingComparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey.A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.Use of cytokines in infection.Telbivudine: an upcoming agent for chronic hepatitis B.Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trialRecommendations and potential future options in the treatment of hepatitis B.CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients.Risk of hepatitis B infections in Olympic wrestlingProgress towards a needle-free hepatitis B vaccine.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.Innate immune responses in hepatitis B virus (HBV) infection.Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease.Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays.Corrective osteotomy in femoral non-union in drug-induced hypophosphataemic osteomalacia.Sodium selenite suppresses hepatitis B virus transcription and replication in human hepatoma cell lines.Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines.The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs?Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc.Detection of YMDD mutants using universal template real-time PCR.Substitution rtq267h of hepatitis B virus increases the weight of replication and Lamivudine resistance.Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B.Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B.Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy.The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection.Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B
P2860
Q33826248-EC860FD2-637F-4E79-98D0-739038108C84Q34555824-6E789FB7-F19D-40CD-862C-CF4CECBC0EE9Q34735876-8E9287E3-9AB7-4C9B-BF01-41602357F91DQ35010535-A804F944-588E-4246-9CB8-0C334D661008Q35595459-CFEEF188-9723-439B-8691-76361355ABC8Q35967372-C57746E5-9D25-4D04-B9DA-7B5A9069E8B5Q36233495-1A5E58B5-0620-4AB0-BC10-423BA96C8AD6Q36308839-53C172B0-2797-4C70-9FF3-B249B3F8B585Q36632233-79432691-B86A-43C7-9D6C-B6ABAE764657Q36898390-C3444EF3-10F4-488D-BB64-1F2068AB1F31Q37136404-45F58960-516F-4655-9D3A-CAD5BACDF701Q37810816-3729218B-F657-4FDD-8968-4F6DDDDE7048Q38027061-266BC73E-F79C-4313-9D76-D75546539E21Q38186180-AB369E11-5845-4255-9AD3-32055196DE84Q38221077-92416576-35AA-45BC-B237-5277183E31C5Q38361837-79BF326C-BDAD-45C3-B302-0976384B9374Q38413721-33EB002D-A0E5-4552-B637-66140B86740FQ38838683-4786D5DF-7B39-4334-8420-7CFD69D7579CQ38844134-6A74C675-8B02-4AA9-B3C7-A95ECD0051F2Q40362295-A3582001-B6B8-4805-A859-848F83474A6CQ40404033-422C5896-715C-4785-AC9A-BD13C02E488AQ40974197-66D5C5F6-0363-4F60-86F5-326FDB65342BQ41878007-599D5D48-8D14-4A72-AAB6-8671685111D5Q42248469-4DEA1044-63DE-44FF-B8B3-A3E9539F06B6Q44946314-15845838-173C-4260-AC57-22A420A45D3DQ45077766-11B9CCED-2A0E-4412-B2E7-C347631B597FQ46414204-304EE63C-16BF-4505-90D2-AADE3F349E4CQ46572233-A8D59230-65A9-461F-9F81-4E05437A8BCFQ47279228-BA324E75-4156-4B7F-8A9D-C8D5E6991307Q58235821-D941134A-A104-4CB4-8BF5-1AAD1A16C214
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Treatment of chronic hepatitis B.
@ast
Treatment of chronic hepatitis B.
@en
Treatment of chronic hepatitis B.
@nl
type
label
Treatment of chronic hepatitis B.
@ast
Treatment of chronic hepatitis B.
@en
Treatment of chronic hepatitis B.
@nl
prefLabel
Treatment of chronic hepatitis B.
@ast
Treatment of chronic hepatitis B.
@en
Treatment of chronic hepatitis B.
@nl
P1476
Treatment of chronic hepatitis B
@en
P2093
P304
P356
10.1016/S1473-3099(01)00118-9
P577
2001-11-01T00:00:00Z